Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Fundamental Analysis

NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD

0.295  -0.02 (-6.05%)

After market: 0.3 +0.01 (+1.69%)

Fundamental Rating

2

Taking everything into account, RLMD scores 2 out of 10 in our fundamental rating. RLMD was compared to 194 industry peers in the Pharmaceuticals industry. While RLMD has a great health rating, there are worries on its profitability. RLMD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RLMD has reported negative net income.
RLMD had a negative operating cash flow in the past year.
RLMD had negative earnings in each of the past 5 years.
In the past 5 years RLMD always reported negative operating cash flow.
RLMD Yearly Net Income VS EBIT VS OCF VS FCFRLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -155.21%, RLMD is doing worse than 86.49% of the companies in the same industry.
RLMD's Return On Equity of -181.60% is on the low side compared to the rest of the industry. RLMD is outperformed by 69.19% of its industry peers.
Industry RankSector Rank
ROA -155.21%
ROE -181.6%
ROIC N/A
ROA(3y)-86.76%
ROA(5y)-96.08%
ROE(3y)-95.99%
ROE(5y)-114.43%
ROIC(3y)N/A
ROIC(5y)N/A
RLMD Yearly ROA, ROE, ROICRLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400

1.3 Margins

RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLMD Yearly Profit, Operating, Gross MarginsRLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, RLMD has about the same amount of shares outstanding.
The number of shares outstanding for RLMD has been increased compared to 5 years ago.
There is no outstanding debt for RLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLMD Yearly Shares OutstandingRLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
RLMD Yearly Total Debt VS Total AssetsRLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

RLMD has an Altman-Z score of -19.38. This is a bad value and indicates that RLMD is not financially healthy and even has some risk of bankruptcy.
RLMD has a worse Altman-Z score (-19.38) than 85.95% of its industry peers.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.38
ROIC/WACCN/A
WACCN/A
RLMD Yearly LT Debt VS Equity VS FCFRLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.88 indicates that RLMD has no problem at all paying its short term obligations.
RLMD has a better Current ratio (6.88) than 73.51% of its industry peers.
RLMD has a Quick Ratio of 6.88. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.88, RLMD is in the better half of the industry, outperforming 74.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.88
RLMD Yearly Current Assets VS Current LiabilitesRLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.45% over the past year.
EPS 1Y (TTM)25.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RLMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.17% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y14.82%
EPS Next 2Y28.2%
EPS Next 3Y14.4%
EPS Next 5Y12.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLMD Yearly Revenue VS EstimatesRLMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2M 4M 6M 8M 10M
RLMD Yearly EPS VS EstimatesRLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLMD Price Earnings VS Forward Price EarningsRLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLMD Per share dataRLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

RLMD's earnings are expected to grow with 14.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.2%
EPS Next 3Y14.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RLMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELMADA THERAPEUTICS INC

NASDAQ:RLMD (2/21/2025, 8:00:01 PM)

After market: 0.3 +0.01 (+1.69%)

0.295

-0.02 (-6.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners29.77%
Inst Owner Change-34.8%
Ins Owners8.69%
Ins Owner Change20.08%
Market Cap8.90M
Analysts47.5
Price Target0.88 (198.31%)
Short Float %3.04%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.95%
Min EPS beat(2)-10.12%
Max EPS beat(2)30.01%
EPS beat(4)3
Avg EPS beat(4)9.39%
Min EPS beat(4)-10.12%
Max EPS beat(4)30.01%
EPS beat(8)6
Avg EPS beat(8)8.41%
EPS beat(12)8
Avg EPS beat(12)5.95%
EPS beat(16)9
Avg EPS beat(16)0.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-92.78%
EPS NQ rev (1m)-15.9%
EPS NQ rev (3m)-15.9%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-2.87
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS0
BVpS1.58
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.21%
ROE -181.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.76%
ROA(5y)-96.08%
ROE(3y)-95.99%
ROE(5y)-114.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.88
Altman-Z -19.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.37%
EPS Next Y14.82%
EPS Next 2Y28.2%
EPS Next 3Y14.4%
EPS Next 5Y12.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.57%
EBIT Next 3Y-6.52%
EBIT Next 5YN/A
FCF growth 1Y49.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.61%
OCF growth 3YN/A
OCF growth 5YN/A